Loading…
Reported covered position: Leg Director, Rep Bob Franks (1997-2000), Leg Correspondent, Rep Charles Taylor (1997), Leg Correspondent, Rep Bill Martini (1995-1996)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Advancing Access to Precision Medicine Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule National Coverage Decision on next generation sequencing tests HR 5062 - Advancing Access to Precision Medicine Act
21st Century Cures Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2018 · third_quarter · 3@
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
21st Century Cures Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
21st Century Cures Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2017 Clinical Lab Fee Schedule rates; reconsideration process
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2016 Clinical Lab Fee Schedule amounts - Gapfill process
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
21st Century Cures Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
21st Century Cures Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics 21st Century Cures (HR 6) Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only)
21st Century Cures Act
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2016 CLFS Payment Determinations
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
HR 4302 - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Patent Transparency and Improvements Act of 2013
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Patent Transparency and Improvements Act of 2013
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Patent Transparency and Improvements Act of 2013
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
America Invents Act (PL 112-29); implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Patent Transparency and Improvements Act of 2013
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
America Invents Act (PL 112-29); implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Patent Transparency and Improvements Act of 2013
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
America Invents Act (PL 112-29); implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Patent Transparency and Improvements Act of 2013
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill Legislation to reauthorize Medical Device User Fee Act (S. 3187, Food and Drug Administration Safety and Innovation Act); laboratory developed test (LDT) requirements FDA draft guidance to regulate laboratory developed tests
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill Legislation to reauthorize Medical Device User Fee Act (not yet introduced); laboratory developed test (LDT) requirements
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
FDA draft guidance to regulate laboratory developed tests Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: MYRIAD GENETIC LABORATORIES, INC.
HR 3207 - legislation to regulate clinical labs
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2018 · third_quarter · 3T
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2018 · second_quarter · Q2
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2018 · first_quarter · Q1
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule National Coverage Decision on next generation sequencing tests HR 5062 - Advancing Access to Precision Medicine Act
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · fourth_quarter · Q4
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule CLFS CY2018 Preliminary Determinations National Coverage Decision on next generation sequencing tests
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · third_quarter · 3A
Patent eligibility
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule CLFS CY2018 Preliminary Determinations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · third_quarter · Q3
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule CLFS CY2018 Preliminary Determinations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · second_quarter · Q2
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Coverage of laboratory developed test under specific LCD Billing rules for laboratory tests; date of service rule/14 day rule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2017 · first_quarter · Q1
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Coverage of laboratory developed test under specific LCD
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2016 · fourth_quarter · Q4
FDA draft guidance to regulate laboratory developed tests, Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2017 Clinical Lab Fee Schedule rates; reconsideration process
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2016 · third_quarter · Q3
FDA draft guidance to regulate laboratory developed tests, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2016 Clinical Lab Fee Schedule amounts - Gapfill process
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2016 · second_quarter · Q2
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2016 · first_quarter · Q1
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2015 · fourth_quarter · Q4
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2016 CLFS Payment Determinations
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2015 · third_quarter · Q3
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
FDA draft guidance to regulate laboratory developed tests and companion diagnostics, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2015 · second_quarter · Q2
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
FDA draft guidance to regulate laboratory developed tests and companion diagnostics 21st Century Cures (HR 6) Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2015 · first_quarter · Q1
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
FDA draft guidance to regulate laboratory developed tests and companion diagnostics 21st Century Cures Discussion Draft; Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2014 · fourth_quarter · Q4
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2014 · second_quarter · 2A
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
America Invents Act (PL 112-29); implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2014 · third_quarter · 3A
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2014 · third_quarter · Q3
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2014 · second_quarter · Q2
America Invents Act (PL 112-29); implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2014 · first_quarter · Q1
America Invents Act (PL 112-29); implementation of the Genetic Testing Study S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
HR 4302 - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2013 · fourth_quarter · Q4
America Invents Act (PL 112-29); implementation of the Genetic Testing Study March-in rights request to NIH; no legislation
Affordable Care Act; implementation of Preventive benefits
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2013 · third_quarter · Q3
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced) Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced) Medicare payment for molecular pathology codes (no legislation introduced)
America Invents Act (PL 112-29); implementation of the Genetic Testing Study March-in rights request to NIH; no legislation
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2013 · second_quarter · Q2
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo Affordable Care Act; Preventive benefits
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced) Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced) Medicare payment for molecular pathology codes (no legislation introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2013 · first_quarter · Q1
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced) Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced) Medicare payment for molecular pathology codes (no legislation introduced)
FDA draft guidance to regulate laboratory developed tests and companion diagnostics Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2012 · fourth_quarter · 4A
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
FDA draft guidance to regulate laboratory developed tests Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2012 · fourth_quarter · Q4
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
FDA draft guidance to regulate laboratory developed tests Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2012 · third_quarter · Q3
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
FDA draft guidance to regulate laboratory developed tests Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P) - Fee schedule placement of genetic tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2012 · second_quarter · Q2
Medicare funding for and beneficiary cost-sharing under Clinical Lab Fee Schedule (The Middle Class Tax Relief & Job Creation Act, PL 112-96 and Budget Control Act of 201, PL 112-225)
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill Legislation to reauthorize Medical Device User Fee Act (S. 3187, Food and Drug Administration Safety and Innovation Act); laboratory developed test (LDT) requirements FDA draft guidance to regulate laboratory developed tests
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2012 · first_quarter · Q1
Medicare funding and beneficiary cost-sharing under Clinical Lab Fee Schedule in The Middle Class Tax Relief & Job Creation Act of 2012 (HR 3630, PL 112-96)
Patient Protection and Affordable Care Act (PPACA, PL 111-148) - preventive services benefit
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill Legislation to reauthorize Medical Device User Fee Act (not yet introduced); laboratory developed test (LDT) requirements
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2011 · fourth_quarter · Q4
Patient Protection and Affordable Care Act (PPACA, PL 111-148) - preventive services benefit
HR 3207 - legislation to regulate clinical labs
Budget Control Act (PL 112-25) - proposals to create copays for clinical lab tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2011 · third_quarter · Q3
Patient Protection and Affordable Care Act (PPACA, PL 111-148) - preventive services benefit
Draft legislation imposing FDA regulation on clinical labs (not yet introduced)
Budget Control Act (PL 112-25) - proposals to create copays for clinical lab tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via MYRIAD GENETIC LABORATORIES, INC.
2011 · third_quarter · RR
Budget Control Act (PL 112-25) Legislation to regulate Laboratory Developed Tests (LDTs) (not yet introduced) PPACA - Patient Protection and Affordable Care Act (PL 111-148) AIA - American Invents Act (PL 112-29)
Budget Control Act (PL 112-25) Legislation to regulate Laboratory Developed Tests (LDTs) (not yet introduced) PPACA - Patient Protection and Affordable Care Act (PL 111-148) AIA - American Invents Act (PL 112-29)
Budget Control Act (PL 112-25) Legislation to regulate Laboratory Developed Tests (LDTs) (not yet introduced) PPACA - Patient Protection and Affordable Care Act (PL 111-148) AIA - American Invents Act (PL 112-29)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced) Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced) Medicare payment for molecular pathology codes (no legislation introduced)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Affordable Care Act; implementation of Preventive benefits
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P) - Fee schedule placement of genetic tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P) - Fee schedule placement of genetic tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Budget Control Act (PL 112-25) Legislation to regulate Laboratory Developed Tests (LDTs) (not yet introduced) PPACA - Patient Protection and Affordable Care Act (PL 111-148) AIA - American Invents Act (PL 112-29)